NTRK‐positive CRC tumors demonstrated very high tumor mutation burden (median 53 mut/MB), microsatellite instability‐high (MSI‐H, 76%), and an enrichment of concurrent POLE and POLD1 mutations. The gene discussed is POLE; the disease is neoplasm.